Loss of consciousness – European Clinical Trials Information Network

Study on Zolpidem’s Effects in Patients with Vision Impairments, Disorders of Consciousness, and Neurotypical Volunteers

Wed, 29 Apr 2026 15:05:49 +0000

This clinical trial is focused on understanding how the medication zolpidem works in different groups of people. The study involves patients with disorders of consciousness, individuals with vision impairments, and neurotypical volunteers, who represent the general population. Some people in these groups have unusual reactions to zolpidem, such as regaining consciousness or temporarily recovering vision. The study aims to explore these unexpected responses to improve personalized care for patients.

The trial will use two medications: zolpidem, which is a film-coated tablet, and mannitol, which is a capsule. Participants will take these medications orally, either by mouth or through a tube if necessary. The study will observe how these medications affect the participants over a short period, with a focus on understanding the unique reactions some people have to zolpidem.

Throughout the study, researchers will monitor various aspects such as consciousness levels, alertness, and cognitive performance. They will also use techniques like high-density electroencephalography (hdEEG) to study brain activity. The findings from this study could lead to better understanding and treatment options for those who experience paradoxical responses to zolpidem.

Study on Apomorphine Hydrochloride and Sodium Chloride for Patients with Severe Brain Injury and Disorders of Consciousness

Wed, 29 Apr 2026 14:59:27 +0000

This clinical trial is focused on treating patients with a severe brain injury, specifically those experiencing a disorder of consciousness. The study will use a medication called apomorphine hydrochloride, which is administered as a solution for infusion through a subcutaneous injection. This means the medication is given under the skin. The purpose of the study is to understand how effective this treatment is for patients who have difficulty being aware of themselves or their surroundings due to their brain injury.

Participants in the study will receive either the apomorphine hydrochloride treatment or a placebo, which is a substance with no active medication. The study will last for a period of up to 30 days. During this time, researchers will monitor changes in the patients’ conditions using various methods, including the Coma Recovery Scale, which helps assess the level of consciousness. Other assessments may include changes in brain activity measured by EEG (a test that detects electrical activity in the brain), and imaging techniques like MRI and PET scans, which provide detailed pictures of the brain.

The study aims to determine if apomorphine hydrochloride can improve the condition of patients with severe brain injuries by enhancing their level of consciousness. Researchers will also look at other factors such as sleep patterns and body temperature changes to gain a comprehensive understanding of the treatment’s effects. The trial is expected to continue until 2028, providing valuable insights into the potential benefits of this treatment for individuals with severe brain injuries.

Study on Ketamine for Treating Patients with Severe Brain Injury and Disorders of Consciousness

Wed, 29 Apr 2026 14:58:31 +0000

This clinical trial is focused on treating patients with disorders of consciousness, which can occur after a severe brain injury. These disorders can include conditions where a person is awake but not aware of themselves or their surroundings. The study is investigating the use of a medication called Ketalar, which contains the active ingredient ketamine. Ketamine is administered as a solution for injection or infusion, meaning it is given directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective ketamine is in improving consciousness in patients who have experienced a coma. The trial will compare the effects of ketamine to a placebo, which is a substance with no active medication. Participants will receive the treatment through an intravenous infusion, which is a method of delivering fluids directly into a vein. The study will monitor any new signs of consciousness, such as the ability to respond to commands, and will also assess changes in brain activity.

Throughout the study, researchers will use various methods to measure brain activity and other physical responses. These methods include fMRI (functional magnetic resonance imaging), which looks at brain activity by detecting changes in blood flow, and EEG (electroencephalogram), which records electrical activity in the brain. The study aims to understand how ketamine affects brain complexity and connectivity, which are important for consciousness. The trial is expected to continue until 2027, providing valuable insights into the potential benefits of ketamine for patients with disorders of consciousness.